Sign In
Buy CDNA
$22.31
+0.240 (+1.09%)
At Close: Jun 03, 2026
CareDx to Participate in Upcoming Investor Conferences
04:01pm, Wednesday, 20'th May 2026
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clini
CareDx Announces Dismissal of 2021 Qui Tam Suit
04:05pm, Monday, 11'th May 2026
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clini
CareDx, Inc. (CDNA) Q1 2026 Earnings Call Transcript
07:43am, Monday, 04'th May 2026
CareDx, Inc. (CDNA) Q1 2026 Earnings Call Transcript
CareDx Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:01pm, Friday, 01'st May 2026
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA), — The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of c
CareDx (CDNA) Q1 Earnings and Revenues Top Estimates
06:48pm, Tuesday, 28'th Apr 2026
CareDx (CDNA) came out with quarterly earnings of $0.34 per share, beating the Zacks Consensus Estimate of $0.11 per share. This compares to earnings of $0.09 per share a year ago.
CareDx Announces Agreement to Acquire Naveris, A Leader in Viral-Mediated Cancer MRD Surveillance Testing
04:05pm, Tuesday, 28'th Apr 2026
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clini
CareDx Announces First Quarter 2026 Financial Results
04:01pm, Tuesday, 28'th Apr 2026
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clini
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clini
CareDx Launches AlloSeq Nano for High-Resolution Rapid HLA Typing
12:42pm, Tuesday, 21'st Apr 2026
CDNA unveils AlloSeq Nano, delivering high-resolution HLA typing in under 3 hours, aiming to boost transplant diagnostics speed and lab efficiency.
CareDx Introduces AlloSeq Nano at EFI 2026, Expanding HLA Typing Portfolio with Long-Read Sequencing
07:05am, Monday, 20'th Apr 2026
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clini
All You Need to Know About CareDx (CDNA) Rating Upgrade to Buy
01:00pm, Friday, 17'th Apr 2026
CareDx (CDNA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
CareDx Sharpens Focus On Core Testing Services
02:37pm, Thursday, 16'th Apr 2026
The transaction, approved by both companies' boards, is expected to close by the end of the third quarter of 2026.
Eurobio scientific signs definitive agreement to acquire CareDx's transplant Lab Product division
02:00am, Thursday, 16'th Apr 2026
EUROBIO SCIENTIFIC SIGNS DEFINITIVE AGREEMENT TO ACQUIRE CAREDX's TRANSPLANT LAB PRODUCT DIVISION Acquisition of CareDx's ‘lab products' portfolio creates new opportunities for growth and innovation
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clini
CareDx to Report First Quarter 2026 Financial Results on April 28, 2026
04:01pm, Tuesday, 14'th Apr 2026
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clini
